1fyt Citations

Structure of a covalently stabilized complex of a human alphabeta T-cell receptor, influenza HA peptide and MHC class II molecule, HLA-DR1.

EMBO J 19 5611-24 (2000)
Cited: 214 times
EuropePMC logo PMID: 11060013

Abstract

An alphabeta T-cell receptor (alphabetaTCR)/hemagglutinin (HA) peptide/human leukocyte antigen (HLA)-DR1 complex was stabilized by flexibly linking the HA peptide with the human HA1.7 alphabetaTCR, to increase the local concentration of the interacting proteins once the peptide has been loaded onto the major histocompatibility complex (MHC) molecule. The structure of the complex, determined by X-ray crystallography, has a binding mode similar to that of the human B7 alphabetaTCR on a pMHCI molecule. Twelve of the 15 MHC residues contacted are at the same positions observed earlier in class I MHC/peptide/TCR complexes. One contact, to an MHC loop outside the peptide-binding site, is conserved and specific to pMHCII complexes. TCR gene usage in the response to HA/HLA-DR appears to conserve charged interactions between three lysines of the peptide and acidic residues on the TCR.

Reviews - 1fyt mentioned but not cited (15)

  1. Evolutionarily conserved amino acids that control TCR-MHC interaction. Marrack P, Scott-Browne JP, Dai S, Gapin L, Kappler JW. Annu Rev Immunol 26 171-203 (2008)
  2. Linkers in the structural biology of protein-protein interactions. Reddy Chichili VP, Kumar V, Sivaraman J. Protein Sci 22 153-167 (2013)
  3. Fundamentals and Methods for T- and B-Cell Epitope Prediction. Sanchez-Trincado JL, Gomez-Perosanz M, Reche PA. J Immunol Res 2017 2680160 (2017)
  4. The structural basis of αβ T-lineage immune recognition: TCR docking topologies, mechanotransduction, and co-receptor function. Wang JH, Reinherz EL. Immunol Rev 250 102-119 (2012)
  5. Structural alterations in peptide-MHC recognition by self-reactive T cell receptors. Wucherpfennig KW, Call MJ, Deng L, Mariuzza R. Curr Opin Immunol 21 590-595 (2009)
  6. TCR recognition of peptide/MHC class II complexes and superantigens. Sundberg EJ, Deng L, Mariuzza RA. Semin Immunol 19 262-271 (2007)
  7. Conformational variation in structures of classical and non-classical MHCII proteins and functional implications. Painter CA, Stern LJ. Immunol Rev 250 144-157 (2012)
  8. Recognition of self-peptide-MHC complexes by autoimmune T-cell receptors. Deng L, Mariuzza RA. Trends Biochem Sci 32 500-508 (2007)
  9. Unusual features of self-peptide/MHC binding by autoimmune T cell receptors. Nicholson MJ, Hahn M, Wucherpfennig KW. Immunity 23 351-360 (2005)
  10. Design and engineering of deimmunized biotherapeutics. Griswold KE, Bailey-Kellogg C. Curr Opin Struct Biol 39 79-88 (2016)
  11. Coevolution of T-cell receptors with MHC and non-MHC ligands. Castro CD, Luoma AM, Adams EJ. Immunol Rev 267 30-55 (2015)
  12. Generation of MHC class II-peptide ligands for CD4 T-cell allorecognition of MHC class II molecules. Leddon SA, Sant AJ. Curr Opin Organ Transplant 15 505-511 (2010)
  13. The versatility of the αβ T-cell antigen receptor. Bhati M, Cole DK, McCluskey J, Sewell AK, Rossjohn J. Protein Sci 23 260-272 (2014)
  14. The Many Faces of CD4+ T Cells: Immunological and Structural Characteristics. Chatzileontiadou DSM, Sloane H, Nguyen AT, Gras S, Grant EJ. Int J Mol Sci 22 (2020)
  15. Streptococcal superantigens and the return of scarlet fever. Hurst JR, Brouwer S, Walker MJ, McCormick JK. PLoS Pathog 17 e1010097 (2021)

Articles - 1fyt mentioned but not cited (53)

  1. Structure of a covalently stabilized complex of a human alphabeta T-cell receptor, influenza HA peptide and MHC class II molecule, HLA-DR1. Hennecke J, Carfi A, Wiley DC. EMBO J 19 5611-5624 (2000)
  2. Unconventional topology of self peptide-major histocompatibility complex binding by a human autoimmune T cell receptor. Hahn M, Nicholson MJ, Pyrdol J, Wucherpfennig KW. Nat Immunol 6 490-496 (2005)
  3. Quantitative predictions of peptide binding to any HLA-DR molecule of known sequence: NetMHCIIpan. Nielsen M, Lundegaard C, Blicher T, Peters B, Sette A, Justesen S, Buus S, Lund O. PLoS Comput Biol 4 e1000107 (2008)
  4. Accurate pan-specific prediction of peptide-MHC class II binding affinity with improved binding core identification. Andreatta M, Karosiene E, Rasmussen M, Stryhn A, Buus S, Nielsen M. Immunogenetics 67 641-650 (2015)
  5. Structure of a human autoimmune TCR bound to a myelin basic protein self-peptide and a multiple sclerosis-associated MHC class II molecule. Li Y, Huang Y, Lue J, Quandt JA, Martin R, Mariuzza RA. EMBO J 24 2968-2979 (2005)
  6. Crossreactive T Cells spotlight the germline rules for alphabeta T cell-receptor interactions with MHC molecules. Dai S, Huseby ES, Rubtsova K, Scott-Browne J, Crawford F, Macdonald WA, Marrack P, Kappler JW. Immunity 28 324-334 (2008)
  7. Specificity and detection of insulin-reactive CD4+ T cells in type 1 diabetes in the nonobese diabetic (NOD) mouse. Crawford F, Stadinski B, Jin N, Michels A, Nakayama M, Pratt P, Marrack P, Eisenbarth G, Kappler JW. Proc Natl Acad Sci U S A 108 16729-16734 (2011)
  8. The design and implementation of the immune epitope database and analysis resource. Peters B, Sidney J, Bourne P, Bui HH, Buus S, Doh G, Fleri W, Kronenberg M, Kubo R, Lund O, Nemazee D, Ponomarenko JV, Sathiamurthy M, Schoenberger SP, Stewart S, Surko P, Way S, Wilson S, Sette A. Immunogenetics 57 326-336 (2005)
  9. Crystal structure of a superantigen bound to MHC class II displays zinc and peptide dependence. Petersson K, Håkansson M, Nilsson H, Forsberg G, Svensson LA, Liljas A, Walse B. EMBO J 20 3306-3312 (2001)
  10. TEPITOPEpan: extending TEPITOPE for peptide binding prediction covering over 700 HLA-DR molecules. Zhang L, Chen Y, Wong HS, Zhou S, Mamitsuka H, Zhu S. PLoS One 7 e30483 (2012)
  11. Human T cell receptor occurrence patterns encode immune history, genetic background, and receptor specificity. DeWitt WS, Smith A, Schoch G, Hansen JA, Matsen FA, Bradley P. Elife 7 e38358 (2018)
  12. High-throughput sequencing of the T-cell receptor repertoire: pitfalls and opportunities. Heather JM, Ismail M, Oakes T, Chain B. Brief Bioinform 19 554-565 (2018)
  13. Structural insights into the editing of germ-line-encoded interactions between T-cell receptor and MHC class II by Vα CDR3. Deng L, Langley RJ, Wang Q, Topalian SL, Mariuzza RA. Proc Natl Acad Sci U S A 109 14960-14965 (2012)
  14. Novel sequence feature variant type analysis of the HLA genetic association in systemic sclerosis. Karp DR, Marthandan N, Marsh SG, Ahn C, Arnett FC, Deluca DS, Diehl AD, Dunivin R, Eilbeck K, Feolo M, Guidry PA, Helmberg W, Lewis S, Mayes MD, Mungall C, Natale DA, Peters B, Petersdorf E, Reveille JD, Smith B, Thomson G, Waller MJ, Scheuermann RH. Hum Mol Genet 19 707-719 (2010)
  15. PREDIVAC: CD4+ T-cell epitope prediction for vaccine design that covers 95% of HLA class II DR protein diversity. Oyarzún P, Ellis JJ, Bodén M, Kobe B. BMC Bioinformatics 14 52 (2013)
  16. Re-Directing CD4(+) T Cell Responses with the Flanking Residues of MHC Class II-Bound Peptides: The Core is Not Enough. Holland CJ, Cole DK, Godkin A. Front Immunol 4 172 (2013)
  17. Modeling the ternary complex TCR-Vbeta/CollagenII(261-273)/HLA-DR4 associated with rheumatoid arthritis. De Rosa MC, Giardina B, Bianchi C, Carelli Alinovi C, Pirolli D, Ferraccioli G, De Santis M, Di Sante G, Ria F. PLoS One 5 e11550 (2010)
  18. Modification of the carboxy-terminal flanking region of a universal influenza epitope alters CD4⁺ T-cell repertoire selection. Cole DK, Gallagher K, Lemercier B, Holland CJ, Junaid S, Hindley JP, Wynn KK, Gostick E, Sewell AK, Gallimore AM, Ladell K, Price DA, Gougeon ML, Godkin A. Nat Commun 3 665 (2012)
  19. Sulfamethoxazole induces a switch mechanism in T cell receptors containing TCRVβ20-1, altering pHLA recognition. Watkins S, Pichler WJ. PLoS One 8 e76211 (2013)
  20. pDOCK: a new technique for rapid and accurate docking of peptide ligands to Major Histocompatibility Complexes. Khan JM, Ranganathan S. Immunome Res 6 Suppl 1 S2 (2010)
  21. Minimal conformational plasticity enables TCR cross-reactivity to different MHC class II heterodimers. Holland CJ, Rizkallah PJ, Vollers S, Calvo-Calle JM, Madura F, Fuller A, Sewell AK, Stern LJ, Godkin A, Cole DK. Sci Rep 2 629 (2012)
  22. IMGT-ONTOLOGY 2012. Giudicelli V, Lefranc MP. Front Genet 3 79 (2012)
  23. Shared peptide binding of HLA Class I and II alleles associate with cutaneous nevirapine hypersensitivity and identify novel risk alleles. Pavlos R, McKinnon EJ, Ostrov DA, Peters B, Buus S, Koelle D, Chopra A, Schutte R, Rive C, Redwood A, Restrepo S, Bracey A, Kaever T, Myers P, Speers E, Malaker SA, Shabanowitz J, Jing Y, Gaudieri S, Hunt DF, Carrington M, Haas DW, Mallal S, Phillips EJ. Sci Rep 7 8653 (2017)
  24. Rational design of T cell receptors with enhanced sensitivity for antigen. Alli R, Zhang ZM, Nguyen P, Zheng JJ, Geiger TL. PLoS One 6 e18027 (2011)
  25. Identification of the cognate peptide-MHC target of T cell receptors using molecular modeling and force field scoring. Lanzarotti E, Marcatili P, Nielsen M. Mol Immunol 94 91-97 (2018)
  26. Identification and Characterization of Complex Glycosylated Peptides Presented by the MHC Class II Processing Pathway in Melanoma. Malaker SA, Ferracane MJ, Depontieu FR, Zarling AL, Shabanowitz J, Bai DL, Topalian SL, Engelhard VH, Hunt DF. J Proteome Res 16 228-237 (2017)
  27. Predicting CD4 T-cell epitopes based on antigen cleavage, MHCII presentation, and TCR recognition. Schneidman-Duhovny D, Khuri N, Dong GQ, Winter MB, Shifrut E, Friedman N, Craik CS, Pratt KP, Paz P, Aswad F, Sali A. PLoS One 13 e0206654 (2018)
  28. Integrated assessment of predicted MHC binding and cross-conservation with self reveals patterns of viral camouflage. He L, De Groot AS, Gutierrez AH, Martin WD, Moise L, Bailey-Kellogg C. BMC Bioinformatics 15 Suppl 4 S1 (2014)
  29. Positioning of autoimmune TCR-Ob.2F3 and TCR-Ob.3D1 on the MBP85-99/HLA-DR2 complex. Kato Z, Stern JN, Nakamura HK, Kuwata K, Kondo N, Strominger JL. Proc Natl Acad Sci U S A 105 15523-15528 (2008)
  30. An effective and effecient peptide binding prediction approach for a broad set of HLA-DR molecules based on ordered weighted averaging of binding pocket profiles. Shen WJ, Zhang S, Wong HS. Proteome Sci 11 S15 (2013)
  31. DynaDom: structure-based prediction of T cell receptor inter-domain and T cell receptor-peptide-MHC (class I) association angles. Hoffmann T, Marion A, Antes I. BMC Struct Biol 17 2 (2017)
  32. MH2c: Characterization of major histocompatibility α-helices - an information criterion approach. Hischenhuber B, Frommlet F, Schreiner W, Knapp B. Comput Phys Commun 183 1481-1490 (2012)
  33. Predicting MHC-II binding affinity using multiple instance regression. EL-Manzalawy Y, Dobbs D, Honavar V. IEEE/ACM Trans Comput Biol Bioinform 8 1067-1079 (2011)
  34. Predicting peptide binding affinities to MHC molecules using a modified semi-empirical scoring function. Liao WW, Arthur JW. PLoS One 6 e25055 (2011)
  35. Quantitative Analysis of the Association Angle between T-cell Receptor Vα/Vβ Domains Reveals Important Features for Epitope Recognition. Hoffmann T, Krackhardt AM, Antes I. PLoS Comput Biol 11 e1004244 (2015)
  36. Types of inter-atomic interactions at the MHC-peptide interface: identifying commonality from accumulated data. Adrian PE, Rajaseger G, Mathura VS, Sakharkar MK, Kangueane P. BMC Struct Biol 2 2 (2002)
  37. Designing of cytotoxic and helper T cell epitope map provides insights into the highly contagious nature of the pandemic novel coronavirus SARS-CoV-2. Mishra S. R Soc Open Sci 7 201141 (2020)
  38. Understanding TR binding to pMHC complexes: how does a TR scan many pMHC complexes yet preferentially bind to one. Khan JM, Ranganathan S. PLoS One 6 e17194 (2011)
  39. A Novel Peptide Binding Prediction Approach for HLA-DR Molecule Based on Sequence and Structural Information. Li Z, Zhao Y, Pan G, Tang J, Guo F. Biomed Res Int 2016 3832176 (2016)
  40. Impact of Structural Observables From Simulations to Predict the Effect of Single-Point Mutations in MHC Class II Peptide Binders. Ochoa R, Laskowski RA, Thornton JM, Cossio P. Front Mol Biosci 8 636562 (2021)
  41. Revisiting the putative TCR Cα dimerization model through structural analysis. Wang JH, Reinherz EL. Front Immunol 4 16 (2013)
  42. Structural Insights Into HLA-DM Mediated MHC II Peptide Exchange. Painter CA, Stern LJ. Curr Top Biochem Res 13 39-55 (2011)
  43. The peptide derived from the Ig-like domain of human herpesvirus 8 K1 protein induces death in hematological cancer cells. Daniluk U, Kerros C, Tao RH, Wise JF, Ao X, Berkova Z, Samaniego F. J Exp Clin Cancer Res 31 69 (2012)
  44. CD4+ T Cells Recognize Conserved Influenza A Epitopes through Shared Patterns of V-Gene Usage and Complementary Biochemical Features. Greenshields-Watson A, Attaf M, MacLachlan BJ, Whalley T, Rius C, Wall A, Lloyd A, Hughes H, Strange KE, Mason GH, Schauenburg AJ, Hulin-Curtis SL, Geary J, Chen Y, Lauder SN, Smart K, Vijaykrishna D, Grau ML, Shugay M, Andrews R, Dolton G, Rizkallah PJ, Gallimore AM, Sewell AK, Godkin AJ, Cole DK. Cell Rep 32 107885 (2020)
  45. An automated framework for understanding structural variations in the binding grooves of MHC class II molecules. Yeturu K, Utriainen T, Kemp GJ, Chandra N. BMC Bioinformatics 11 Suppl 1 S55 (2010)
  46. Conserved biophysical compatibility among the highly variable germline-encoded regions shapes TCR-MHC interactions. Boughter CT, Meier-Schellersheim M. Elife 12 e90681 (2023)
  47. Molecular engineering strategies for visualizing low-affinity protein complexes. Ming Q, Gonzalez-Perez D, Luca VC. Exp Biol Med (Maywood) 244 1559-1567 (2019)
  48. TCR-pMHC: Envisioning the specialized dynamics of the target 5-component complex. Murray JS. Cell Mol Immunol 19 657-659 (2022)
  49. A conserved multi-epitope-based vaccine designed by targeting hemagglutinin protein of highly pathogenic avian H5 influenza viruses. Islam MSB, Miah M, Hossain ME, Kibria KMK. 3 Biotech 10 546 (2020)
  50. Activating interactions of sulfanilamides with T cell receptors. Watkins S, Pichler WJ. Open J Immunol 3 139-157 (2013)
  51. Computational discovery of binding mode of anti-TRBC1 antibody and predicted key amino acids of TRBC1. Saetang J, Sangkhathat S, Jangphattananont N, Khopanlert W, Julamanee J, Tipmanee V. Sci Rep 12 1760 (2022)
  52. Nanoparticle-based modulation of CD4+ T cell effector and helper functions enhances adoptive immunotherapy. Isser A, Silver AB, Pruitt HC, Mass M, Elias EH, Aihara G, Kang SS, Bachmann N, Chen YY, Leonard EK, Bieler JG, Chaisawangwong W, Choy J, Shannon SR, Gerecht S, Weber JS, Spangler JB, Schneck JP. Nat Commun 13 6086 (2022)
  53. PANDORA v2.0: Benchmarking peptide-MHC II models and software improvements. Parizi FM, Marzella DF, Ramakrishnan G, 't Hoen PAC, Karimi-Jafari MH, Xue LC. Front Immunol 14 1285899 (2023)


Reviews citing this publication (29)

  1. How TCRs bind MHCs, peptides, and coreceptors. Rudolph MG, Stanfield RL, Wilson IA. Annu Rev Immunol 24 419-466 (2006)
  2. Molecular interactions mediating T cell antigen recognition. van der Merwe PA, Davis SJ. Annu Rev Immunol 21 659-684 (2003)
  3. T cell antigen receptor recognition of antigen-presenting molecules. Rossjohn J, Gras S, Miles JJ, Turner SJ, Godfrey DI, McCluskey J. Annu Rev Immunol 33 169-200 (2015)
  4. Structure and function of natural killer cell receptors: multiple molecular solutions to self, nonself discrimination. Natarajan K, Dimasi N, Wang J, Mariuzza RA, Margulies DH. Annu Rev Immunol 20 853-885 (2002)
  5. The specificity of TCR/pMHC interaction. Rudolph MG, Wilson IA. Curr Opin Immunol 14 52-65 (2002)
  6. T cell receptor-MHC interactions up close. Hennecke J, Wiley DC. Cell 104 1-4 (2001)
  7. The immunopathogenesis of rheumatoid arthritis. Imboden JB. Annu Rev Pathol 4 417-434 (2009)
  8. The fidelity, occasional promiscuity, and versatility of T cell receptor recognition. Godfrey DI, Rossjohn J, McCluskey J. Immunity 28 304-314 (2008)
  9. What do TCR-pMHC crystal structures teach us about MHC restriction and alloreactivity? Housset D, Malissen B. Trends Immunol 24 429-437 (2003)
  10. Structural and thermodynamic correlates of T cell signaling. Rudolph MG, Luz JG, Wilson IA. Annu Rev Biophys Biomol Struct 31 121-149 (2002)
  11. Staphylococcal superantigens in colonization and disease. Xu SX, McCormick JK. Front Cell Infect Microbiol 2 52 (2012)
  12. Structural basis of molecular mimicry. Wucherpfennig KW. J Autoimmun 16 293-302 (2001)
  13. Structural basis of T cell recognition of peptides bound to MHC molecules. Wang JH, Reinherz EL. Mol Immunol 38 1039-1049 (2002)
  14. HLA class II tetramers: tools for direct analysis of antigen-specific CD4+ T cells. Nepom GT, Buckner JH, Novak EJ, Reichstetter S, Reijonen H, Gebe J, Wang R, Swanson E, Kwok WW. Arthritis Rheum 46 5-12 (2002)
  15. Structural basis for self-recognition by autoimmune T-cell receptors. Yin Y, Li Y, Mariuzza RA. Immunol Rev 250 32-48 (2012)
  16. Interplay between superantigens and immunoreceptors. Petersson K, Forsberg G, Walse B. Scand J Immunol 59 345-355 (2004)
  17. Molecular aspects of type 1 diabetes. Kelly MA, Rayner ML, Mijovic CH, Barnett AH. Mol Pathol 56 1-10 (2003)
  18. T cells and their eons-old obsession with MHC. Yin L, Scott-Browne J, Kappler JW, Gapin L, Marrack P. Immunol Rev 250 49-60 (2012)
  19. So many ways of getting in the way: diversity in the molecular architecture of superantigen-dependent T-cell signaling complexes. Sundberg EJ, Li Y, Mariuzza RA. Curr Opin Immunol 14 36-44 (2002)
  20. T-cell allorecognition: a case of mistaken identity or déjà vu? Archbold JK, Macdonald WA, Burrows SR, Rossjohn J, McCluskey J. Trends Immunol 29 220-226 (2008)
  21. TCR-MHC docking orientation: natural selection, or thymic selection? Collins EJ, Riddle DS. Immunol Res 41 267-294 (2008)
  22. Dissection of the multiple sclerosis associated DR2 haplotype. Etzensperger R, McMahon RM, Jones EY, Fugger L. J Autoimmun 31 201-207 (2008)
  23. T cell receptor specificity for major histocompatibility complex proteins. Marrack P, Rubtsova K, Scott-Browne J, Kappler JW. Curr Opin Immunol 20 203-207 (2008)
  24. Prediction of T-cell epitope. Tsurui H, Takahashi T. J Pharmacol Sci 105 299-316 (2007)
  25. Strategies for developing multi-epitope, subunit-based, chemically synthesized anti-malarial vaccines. Patarroyo ME, Cifuentes G, Bermúdez A, Patarroyo MA. J Cell Mol Med 12 1915-1935 (2008)
  26. Some lessons from the systematic production and structural analysis of soluble (alpha)(beta) T-cell receptors. van Boxel GI, Stewart-Jones G, Holmes S, Sainsbury S, Shepherd D, Gillespie GM, Harlos K, Stuart DI, Owens R, Jones EY. J Immunol Methods 350 14-21 (2009)
  27. MHC Class II Presentation in Autoimmunity. Ishina IA, Zakharova MY, Kurbatskaia IN, Mamedov AE, Belogurov AA, Gabibov AG. Cells 12 314 (2023)
  28. Assembling atomic resolution views of the immunological synapse. Wang JH, Eck MJ. Curr Opin Immunol 15 286-293 (2003)
  29. Novel insights into the immune response to bacterial T cell superantigens. Tuffs SW, Dufresne K, Rishi A, Walton NR, McCormick JK. Nat Rev Immunol (2024)

Articles citing this publication (117)

  1. A functional and structural basis for TCR cross-reactivity in multiple sclerosis. Lang HL, Jacobsen H, Ikemizu S, Andersson C, Harlos K, Madsen L, Hjorth P, Sondergaard L, Svejgaard A, Wucherpfennig K, Stuart DI, Bell JI, Jones EY, Fugger L. Nat Immunol 3 940-943 (2002)
  2. Enhancement to the RANKPEP resource for the prediction of peptide binding to MHC molecules using profiles. Reche PA, Glutting JP, Zhang H, Reinherz EL. Immunogenetics 56 405-419 (2004)
  3. CDR3 loop flexibility contributes to the degeneracy of TCR recognition. Reiser JB, Darnault C, Grégoire C, Mosser T, Mazza G, Kearney A, van der Merwe PA, Fontecilla-Camps JC, Housset D, Malissen B. Nat Immunol 4 241-247 (2003)
  4. Structural evidence for a germline-encoded T cell receptor-major histocompatibility complex interaction 'codon'. Feng D, Bond CJ, Ely LK, Maynard J, Garcia KC. Nat Immunol 8 975-983 (2007)
  5. A T cell receptor CDR3beta loop undergoes conformational changes of unprecedented magnitude upon binding to a peptide/MHC class I complex. Reiser JB, Grégoire C, Darnault C, Mosser T, Guimezanes A, Schmitt-Verhulst AM, Fontecilla-Camps JC, Mazza G, Malissen B, Housset D. Immunity 16 345-354 (2002)
  6. Crystal structure of the human CD4 N-terminal two-domain fragment complexed to a class II MHC molecule. Wang JH, Meijers R, Xiong Y, Liu JH, Sakihama T, Zhang R, Joachimiak A, Reinherz EL. Proc Natl Acad Sci U S A 98 10799-10804 (2001)
  7. Human TCR-binding affinity is governed by MHC class restriction. Cole DK, Pumphrey NJ, Boulter JM, Sami M, Bell JI, Gostick E, Price DA, Gao GF, Sewell AK, Jakobsen BK. J Immunol 178 5727-5734 (2007)
  8. The CDR3 regions of an immunodominant T cell receptor dictate the 'energetic landscape' of peptide-MHC recognition. Borg NA, Ely LK, Beddoe T, Macdonald WA, Reid HH, Clements CS, Purcell AW, Kjer-Nielsen L, Miles JJ, Burrows SR, McCluskey J, Rossjohn J. Nat Immunol 6 171-180 (2005)
  9. Structure of a complex of the human alpha/beta T cell receptor (TCR) HA1.7, influenza hemagglutinin peptide, and major histocompatibility complex class II molecule, HLA-DR4 (DRA*0101 and DRB1*0401): insight into TCR cross-restriction and alloreactivity. Hennecke J, Wiley DC. J Exp Med 195 571-581 (2002)
  10. Structure of an autoimmune T cell receptor complexed with class II peptide-MHC: insights into MHC bias and antigen specificity. Maynard J, Petersson K, Wilson DH, Adams EJ, Blondelle SE, Boulanger MJ, Wilson DB, Garcia KC. Immunity 22 81-92 (2005)
  11. Mechanisms contributing to T cell receptor signaling and assembly revealed by the solution structure of an ectodomain fragment of the CD3 epsilon gamma heterodimer. Sun ZJ, Kim KS, Wagner G, Reinherz EL. Cell 105 913-923 (2001)
  12. The spectrum of HLA-DQ and HLA-DR alleles, 2006: a listing correlating sequence and structure with function. Bondinas GP, Moustakas AK, Papadopoulos GK. Immunogenetics 59 539-553 (2007)
  13. Structure of the Epstein-Barr virus gp42 protein bound to the MHC class II receptor HLA-DR1. Mullen MM, Haan KM, Longnecker R, Jardetzky TS. Mol Cell 9 375-385 (2002)
  14. Vgamma2Vdelta2 T Cell Receptor recognition of prenyl pyrophosphates is dependent on all CDRs. Wang H, Fang Z, Morita CT. J Immunol 184 6209-6222 (2010)
  15. A correlation between TCR Valpha docking on MHC and CD8 dependence: implications for T cell selection. Buslepp J, Wang H, Biddison WE, Appella E, Collins EJ. Immunity 19 595-606 (2003)
  16. A new type of metal recognition by human T cells: contact residues for peptide-independent bridging of T cell receptor and major histocompatibility complex by nickel. Gamerdinger K, Moulon C, Karp DR, Van Bergen J, Koning F, Wild D, Pflugfelder U, Weltzien HU. J Exp Med 197 1345-1353 (2003)
  17. Structural comparison of allogeneic and syngeneic T cell receptor-peptide-major histocompatibility complex complexes: a buried alloreactive mutation subtly alters peptide presentation substantially increasing V(beta) Interactions. Luz JG, Huang M, Garcia KC, Rudolph MG, Apostolopoulos V, Teyton L, Wilson IA. J Exp Med 195 1175-1186 (2002)
  18. Surface-anchored monomeric agonist pMHCs alone trigger TCR with high sensitivity. Ma Z, Sharp KA, Janmey PA, Finkel TH. PLoS Biol 6 e43 (2008)
  19. The majority of immunogenic epitopes generate CD4+ T cells that are dependent on MHC class II-bound peptide-flanking residues. Arnold PY, La Gruta NL, Miller T, Vignali KM, Adams PS, Woodland DL, Vignali DA. J Immunol 169 739-749 (2002)
  20. Tom20 recognizes mitochondrial presequences through dynamic equilibrium among multiple bound states. Saitoh T, Igura M, Obita T, Ose T, Kojima R, Maenaka K, Endo T, Kohda D. EMBO J 26 4777-4787 (2007)
  21. A highly tilted binding mode by a self-reactive T cell receptor results in altered engagement of peptide and MHC. Sethi DK, Schubert DA, Anders AK, Heroux A, Bonsor DA, Thomas CP, Sundberg EJ, Pyrdol J, Wucherpfennig KW. J Exp Med 208 91-102 (2011)
  22. Components of the ligand for a Ni++ reactive human T cell clone. Lu L, Vollmer J, Moulon C, Weltzien HU, Marrack P, Kappler J. J Exp Med 197 567-574 (2003)
  23. Stoichiometry of the T-cell receptor-CD3 complex and key intermediates assembled in the endoplasmic reticulum. Call ME, Pyrdol J, Wucherpfennig KW. EMBO J 23 2348-2357 (2004)
  24. T cells distinguish MHC-peptide complexes formed in separate vesicles and edited by H2-DM. Pu Z, Lovitch SB, Bikoff EK, Unanue ER. Immunity 20 467-476 (2004)
  25. Staining of celiac disease-relevant T cells by peptide-DQ2 multimers. Quarsten H, McAdam SN, Jensen T, Arentz-Hansen H, Molberg Ø, Lundin KE, Sollid LM. J Immunol 167 4861-4868 (2001)
  26. Crystal structure of MHC class II I-Ab in complex with a human CLIP peptide: prediction of an I-Ab peptide-binding motif. Zhu Y, Rudensky AY, Corper AL, Teyton L, Wilson IA. J Mol Biol 326 1157-1174 (2003)
  27. Structural basis for the recognition of mutant self by a tumor-specific, MHC class II-restricted T cell receptor. Deng L, Langley RJ, Brown PH, Xu G, Teng L, Wang Q, Gonzales MI, Callender GG, Nishimura MI, Topalian SL, Mariuzza RA. Nat Immunol 8 398-408 (2007)
  28. Interference with T cell receptor-HLA-DR interactions by Epstein-Barr virus gp42 results in reduced T helper cell recognition. Ressing ME, van Leeuwen D, Verreck FA, Gomez R, Heemskerk B, Toebes M, Mullen MM, Jardetzky TS, Longnecker R, Schilham MW, Ottenhoff TH, Neefjes J, Schumacher TN, Hutt-Fletcher LM, Wiertz EJ. Proc Natl Acad Sci U S A 100 11583-11588 (2003)
  29. The 1.5 A crystal structure of a highly selected antiviral T cell receptor provides evidence for a structural basis of immunodominance. Kjer-Nielsen L, Clements CS, Brooks AG, Purcell AW, McCluskey J, Rossjohn J. Structure 10 1521-1532 (2002)
  30. Alternate interactions define the binding of peptides to the MHC molecule IA(b). Liu X, Dai S, Crawford F, Fruge R, Marrack P, Kappler J. Proc Natl Acad Sci U S A 99 8820-8825 (2002)
  31. Prevalent role of TCR alpha-chain in the selection of the preimmune repertoire specific for a human tumor-associated self-antigen. Dietrich PY, Le Gal FA, Dutoit V, Pittet MJ, Trautman L, Zippelius A, Cognet I, Widmer V, Walker PR, Michielin O, Guillaume P, Connerotte T, Jotereau F, Coulie PG, Romero P, Cerottini JC, Bonneville M, Valmori D. J Immunol 170 5103-5109 (2003)
  32. Predominant role of T cell receptor (TCR)-alpha chain in forming preimmune TCR repertoire revealed by clonal TCR reconstitution system. Yokosuka T, Takase K, Suzuki M, Nakagawa Y, Taki S, Takahashi H, Fujisawa T, Arase H, Saito T. J Exp Med 195 991-1001 (2002)
  33. Prediction of multimolecular assemblies by multiple docking. Inbar Y, Benyamini H, Nussinov R, Wolfson HJ. J Mol Biol 349 435-447 (2005)
  34. A hairpin turn in a class II MHC-bound peptide orients residues outside the binding groove for T cell recognition. Zavala-Ruiz Z, Strug I, Walker BD, Norris PJ, Stern LJ. Proc Natl Acad Sci U S A 101 13279-13284 (2004)
  35. Distinct recognition by two subsets of T cells of an MHC class II-peptide complex. Pu Z, Carrero JA, Unanue ER. Proc Natl Acad Sci U S A 99 8844-8849 (2002)
  36. Structural basis of specificity and cross-reactivity in T cell receptors specific for cytochrome c-I-E(k). Newell EW, Ely LK, Kruse AC, Reay PA, Rodriguez SN, Lin AE, Kuhns MS, Garcia KC, Davis MM. J Immunol 186 5823-5832 (2011)
  37. The properties of the single chicken MHC classical class II alpha chain ( B-LA) gene indicate an ancient origin for the DR/E-like isotype of class II molecules. Salomonsen J, Marston D, Avila D, Bumstead N, Johansson B, Juul-Madsen H, Olesen GD, Riegert P, Skjødt K, Vainio O, Wiles MV, Kaufman J. Immunogenetics 55 605-614 (2003)
  38. DM loss in k haplotype mice reveals isotype-specific chaperone requirements. Koonce CH, Wutz G, Robertson EJ, Vogt AB, Kropshofer H, Bikoff EK. J Immunol 170 3751-3761 (2003)
  39. HistoCheck: rating of HLA class I and II mismatches by an internet-based software tool. Elsner HA, DeLuca D, Strub J, Blasczyk R. Bone Marrow Transplant 33 165-169 (2004)
  40. Structural basis of cytochrome c presentation by IE(k). Fremont DH, Dai S, Chiang H, Crawford F, Marrack P, Kappler J. J Exp Med 195 1043-1052 (2002)
  41. Functional consequences of HLA-DQ8 homozygosity versus heterozygosity for islet autoimmunity in type 1 diabetes. Eerligh P, van Lummel M, Zaldumbide A, Moustakas AK, Duinkerken G, Bondinas G, Koeleman BP, Papadopoulos GK, Roep BO. Genes Immun 12 415-427 (2011)
  42. alpha beta T cell receptor ligand-specific oligomerization revisited. Baker BM, Wiley DC. Immunity 14 681-692 (2001)
  43. Toward an atomistic understanding of the immune synapse: large-scale molecular dynamics simulation of a membrane-embedded TCR-pMHC-CD4 complex. Wan S, Flower DR, Coveney PV. Mol Immunol 45 1221-1230 (2008)
  44. Selective modulation of CD4+ T cells from lupus patients by a promiscuous, protective peptide analog. Monneaux F, Hoebeke J, Sordet C, Nonn C, Briand JP, Maillère B, Sibillia J, Muller S. J Immunol 175 5839-5847 (2005)
  45. Identification of MHC class IIbeta resistance/susceptibility alleles to Aeromonas salmonicida in brook charr (Salvelinus fontinalis). Croisetière S, Tarte PD, Bernatchez L, Belhumeur P. Mol Immunol 45 3107-3116 (2008)
  46. Crystal structure of a SEA variant in complex with MHC class II reveals the ability of SEA to crosslink MHC molecules. Petersson K, Thunnissen M, Forsberg G, Walse B. Structure 10 1619-1626 (2002)
  47. Multiplex Identification of Antigen-Specific T Cell Receptors Using a Combination of Immune Assays and Immune Receptor Sequencing. Klinger M, Pepin F, Wilkins J, Asbury T, Wittkop T, Zheng J, Moorhead M, Faham M. PLoS One 10 e0141561 (2015)
  48. Optogenetic control shows that kinetic proofreading regulates the activity of the T cell receptor. Yousefi OS, Günther M, Hörner M, Chalupsky J, Wess M, Brandl SM, Smith RW, Fleck C, Kunkel T, Zurbriggen MD, Höfer T, Weber W, Schamel WW. Elife 8 (2019)
  49. Dominant TCR-alpha requirements for a self antigen recognition in humans. Mantovani S, Palermo B, Garbelli S, Campanelli R, Robustelli Della Cuna G, Gennari R, Benvenuto F, Lantelme E, Giachino C. J Immunol 169 6253-6260 (2002)
  50. Peptide length significantly influences in vitro affinity for MHC class II molecules. O'Brien C, Flower DR, Feighery C. Immunome Res 4 6 (2008)
  51. A molecular marker for thymocyte-positive selection: selection of CD4 single-positive thymocytes with shorter TCRB CDR3 during T cell development. Yassai M, Ammon K, Goverman J, Marrack P, Naumov Y, Gorski J. J Immunol 168 3801-3807 (2002)
  52. T-cell recognition of HLA-DQ2-bound gluten peptides can be influenced by an N-terminal proline at p-1. Stepniak D, Vader LW, Kooy Y, van Veelen PA, Moustakas A, Papandreou NA, Eliopoulos E, Drijfhout JW, Papadopoulos GK, Koning F. Immunogenetics 57 8-15 (2005)
  53. The diabetogenic mouse MHC class II molecule I-Ag7 is endowed with a switch that modulates TCR affinity. Yoshida K, Corper AL, Herro R, Jabri B, Wilson IA, Teyton L. J Clin Invest 120 1578-1590 (2010)
  54. Involvement of the TCR Cbeta FG loop in thymic selection and T cell function. Sasada T, Touma M, Chang HC, Clayton LK, Wang JH, Reinherz EL. J Exp Med 195 1419-1431 (2002)
  55. Crossreactivity of a human autoimmune TCR is dominated by a single TCR loop. Sethi DK, Gordo S, Schubert DA, Wucherpfennig KW. Nat Commun 4 2623 (2013)
  56. Identification of human T cell epitopes in Japanese cypress pollen allergen, Cha o 1, elucidates the intrinsic mechanism of cross-allergenicity between Cha o 1 and Cry j 1, the major allergen of Japanese cedar pollen, at the T cell level. Sone T, Dairiki K, Morikubo K, Shimizu K, Tsunoo H, Mori T, Kino K. Clin Exp Allergy 35 664-671 (2005)
  57. Systematic analysis of the combinatorial nature of epitopes recognized by TCR leads to identification of mimicry epitopes for glutamic acid decarboxylase 65-specific TCRs. Uemura Y, Senju S, Maenaka K, Iwai LK, Fujii S, Tabata H, Tsukamoto H, Hirata S, Chen YZ, Nishimura Y. J Immunol 170 947-960 (2003)
  58. A new twist in TCR diversity revealed by a forbidden alphabeta TCR. McBeth C, Seamons A, Pizarro JC, Fleishman SJ, Baker D, Kortemme T, Goverman JM, Strong RK. J Mol Biol 375 1306-1319 (2008)
  59. A structural basis for CD8+ T cell-dependent recognition of non-homologous peptide ligands: implications for molecular mimicry in autoreactivity. Sandalova T, Michaëlsson J, Harris RA, Odeberg J, Schneider G, Kärre K, Achour A. J Biol Chem 280 27069-27075 (2005)
  60. Comparison of CDR3 length among thymocyte subpopulations: impacts of MHC and BV segment on the CDR3 shortening. Matsutani T, Ohmori T, Ogata M, Soga H, Kasahara S, Yoshioka T, Suzuki R, Itoh T. Mol Immunol 44 2378-2387 (2007)
  61. TCR/pMHC Optimized Protein crystallization Screen. Bulek AM, Madura F, Fuller A, Holland CJ, Schauenburg AJ, Sewell AK, Rizkallah PJ, Cole DK. J Immunol Methods 382 203-210 (2012)
  62. Crystal structure of Mycoplasma arthritidis mitogen complexed with HLA-DR1 reveals a novel superantigen fold and a dimerized superantigen-MHC complex. Zhao Y, Li Z, Drozd SJ, Guo Y, Mourad W, Li H. Structure 12 277-288 (2004)
  63. Molecular dynamics at the receptor level of immunodominant myelin basic protein epitope 87-99 implicated in multiple sclerosis and its antagonists altered peptide ligands: triggering of immune response. Mantzourani ED, Platts JA, Brancale A, Mavromoustakos TM, Tselios TV. J Mol Graph Model 26 471-481 (2007)
  64. T cell selection and differential activation on structurally related HLA-DR4 ligands. Gebe JA, Novak EJ, Kwok WW, Farr AG, Nepom GT, Buckner JH. J Immunol 167 3250-3256 (2001)
  65. Cutting edge: Evidence of direct TCR alpha-chain interaction with superantigen. Pumphrey N, Vuidepot A, Jakobsen B, Forsberg G, Walse B, Lindkvist-Petersson K. J Immunol 179 2700-2704 (2007)
  66. IMPIPS: the immune protection-inducing protein structure concept in the search for steric-electron and topochemical principles for complete fully-protective chemically synthesised vaccine development. Patarroyo ME, Bermúdez A, Alba MP, Vanegas M, Moreno-Vranich A, Poloche LA, Patarroyo MA. PLoS One 10 e0123249 (2015)
  67. Mutations changing the kinetics of class II MHC peptide exchange. Wilson N, Fremont D, Marrack P, Kappler J. Immunity 14 513-522 (2001)
  68. NMR and molecular dynamics studies of an autoimmune myelin basic protein peptide and its antagonist: structural implications for the MHC II (I-Au)-peptide complex from docking calculations. Tzakos AG, Fuchs P, van Nuland NA, Troganis A, Tselios T, Deraos S, Matsoukas J, Gerothanassis IP, Bonvin AM. Eur J Biochem 271 3399-3413 (2004)
  69. The DY genes of the cattle MHC: expression and comparative analysis of an unusual class II MHC gene pair. Ballingall KT, Ellis SA, MacHugh ND, Archibald SD, McKeever DJ. Immunogenetics 55 748-755 (2004)
  70. 3D analysis of the TCR/pMHCII complex formation in monkeys vaccinated with the first peptide inducing sterilizing immunity against human malaria. Patarroyo MA, Bermúdez A, López C, Yepes G, Patarroyo ME. PLoS One 5 e9771 (2010)
  71. Cutting edge: TCR contacts as anchors: effects on affinity and HLA-DM stability. Anderson MW, Gorski J. J Immunol 171 5683-5687 (2003)
  72. Research Support, U.S. Gov't, P.H.S. Major histocompatibility complex proteins and TCRs: do they really go together like a horse and carriage? Marrack P, Bender J, Jordan M, Rees W, Robertson J, Schaefer BC, Kappler J. J Immunol 167 617-621 (2001)
  73. Glycopeptide specificity of helper T cells obtained in mouse models for rheumatoid arthritis. Holm B, Bäcklund J, Recio MA, Holmdahl R, Kihlberg J. Chembiochem 3 1209-1222 (2002)
  74. T cell recognition of distinct peptide:I-Au conformers in murine experimental autoimmune encephalomyelitis. Huang JC, Han M, Minguela A, Pastor S, Qadri A, Ward ES. J Immunol 171 2467-2477 (2003)
  75. A combined NMR and molecular dynamics simulation study to determine the conformational properties of agonists and antagonists against experimental autoimmune encephalomyelitis. Mantzourani ED, Blokar K, Tselios TV, Matsoukas JM, Platts JA, Mavromoustakos TM, Grdadolnik SG. Bioorg Med Chem 16 2171-2182 (2008)
  76. A novel MHCp binding prediction model. Zhao B, Mathura VS, Rajaseger G, Moochhala S, Sakharkar MK, Kangueane P. Hum Immunol 64 1123-1143 (2003)
  77. Gauche(+) side-chain orientation as a key factor in the search for an immunogenic peptide mixture leading to a complete fully protective vaccine. Bermúdez A, Calderon D, Moreno-Vranich A, Almonacid H, Patarroyo MA, Poloche A, Patarroyo ME. Vaccine 32 2117-2126 (2014)
  78. The T cell receptor beta-chain second complementarity determining region loop (CDR2beta governs T cell activation and Vbeta specificity by bacterial superantigens. Nur-ur Rahman AK, Bonsor DA, Herfst CA, Pollard F, Peirce M, Wyatt AW, Kasper KJ, Madrenas J, Sundberg EJ, McCormick JK. J Biol Chem 286 4871-4881 (2011)
  79. Peptide binding to the HLA-DRB1 supertype: a proteochemometrics analysis. Dimitrov I, Garnev P, Flower DR, Doytchinova I. Eur J Med Chem 45 236-243 (2010)
  80. Prediction of the unknown: inspiring experience with the CAPRI experiment. Ben-Zeev E, Berchanski A, Heifetz A, Shapira B, Eisenstein M. Proteins 52 41-46 (2003)
  81. Crystal structure of a T cell receptor Valpha11 (AV11S5) domain: new canonical forms for the first and second complementarity determining regions. Machius M, Cianga P, Deisenhofer J, Ward ES. J Mol Biol 310 689-698 (2001)
  82. Characterization of the MHC class II α-chain gene in ducks. Ren L, Yang Z, Wang T, Sun Y, Guo Y, Zhang Z, Fei J, Bao Y, Qin T, Wang J, Huang Y, Hu X, Zhao Y, Li N. Immunogenetics 63 667-678 (2011)
  83. Recognition of T cell epitopes unique to Cha o 2, the major allergen in Japanese cypress pollen, in allergic patients cross-reactive to Japanese cedar and Japanese cypress pollen. Sone T, Dairiki K, Morikubo K, Shimizu K, Tsunoo H, Mori T, Kino K. Allergol Int 58 237-245 (2009)
  84. Vaccine Strain-Specificity of Protective HLA-Restricted Class 1 P. falciparum Epitopes. Sedegah M, Peters B, Hollingdale MR, Ganeshan HD, Huang J, Farooq F, Belmonte MN, Belmonte AD, Limbach KJ, Diggs C, Soisson L, Chuang I, Villasante ED. PLoS One 11 e0163026 (2016)
  85. Involvement of zinc in the binding of Mycoplasma arthritidis-derived mitogen to the proximity of the HLA-DR binding groove regardless of histidine 81 of the beta chain. Etongué-Mayer P, Langlois MA, Ouellette M, Li H, Younes S, Al-Daccak R, Mourad W. Eur J Immunol 32 50-58 (2002)
  86. Altered peptide ligands can modify the Th2 T cell response to the immunodominant 161-175 peptide of LACK (Leishmania homolog for the receptor of activated C kinase). Jensen KD, Sercarz EE, Gabaglia CR. Mol Immunol 46 366-374 (2009)
  87. Identification of an altered peptide ligand based on the endogenously presented, rheumatoid arthritis-associated, human cartilage glycoprotein-39(263-275) epitope: an MHC anchor variant peptide for immune modulation. Boots AM, Hubers H, Kouwijzer M, den Hoed-van Zandbrink L, Westrek-Esselink BM, van Doorn C, Stenger R, Bos ES, van Lierop MJ, Verheijden GF, Timmers CM, van Staveren CJ. Arthritis Res Ther 9 R71 (2007)
  88. Energetic and flexibility properties captured by long molecular dynamics simulations of a membrane-embedded pMHCII-TCR complex. Bello M, Correa-Basurto J. Mol Biosyst 12 1350-1366 (2016)
  89. Structure of Staphylococcal Enterotoxin E in Complex with TCR Defines the Role of TCR Loop Positioning in Superantigen Recognition. Rödström KE, Regenthal P, Lindkvist-Petersson K. PLoS One 10 e0131988 (2015)
  90. The first structures of T cell receptors bound to peptide-MHC. Wucherpfennig KW. J Immunol 185 6391-6393 (2010)
  91. Assessment of differences in HLA-A, -B, and -DRB1 allele mismatches among African-American and non-African-American recipients of deceased kidney transplants. Kamoun M, Israni AK, Joffe MM, Hoy T, Kearns J, Mange KC, Feldman D, Goodman N, Rosas SE, Abrams JD, Brayman KL, Feldman HI. Transplant Proc 39 55-63 (2007)
  92. Crystal structures of T cell receptor (beta) chains related to rheumatoid arthritis. Li H, Van Vranken S, Zhao Y, Li Z, Guo Y, Eisele L, Li Y. Protein Sci 14 3025-3038 (2005)
  93. HLA homology within the C5 domain promotes peptide binding by HIV type 1 gp120. Cadogan M, Austen B, Heeney JL, Dalgleish AG. AIDS Res Hum Retroviruses 24 845-855 (2008)
  94. Investigation of the function of the putative self-association site of Epstein-Barr virus (EBV) glycoprotein 42 (gp42). Rowe CL, Matsuura H, Jardetzky TS, Longnecker R. Virology 415 122-131 (2011)
  95. Comment MHC restriction: slip-sliding away. Wilson IA, Stanfield RL. Nat Immunol 6 434-435 (2005)
  96. Sea bass (Dicentrarchus labrax) invariant chain and class II major histocompatibility complex: sequencing and structural analysis using 3D homology modelling. Silva DS, Reis MI, Nascimento DS, do Vale A, Pereira PJ, dos Santos NM. Mol Immunol 44 3758-3776 (2007)
  97. Shortening of complementarity determining region 3 of the T cell receptor α chain during thymocyte development. Matsutani T, Ogata M, Fujii Y, Kitaura K, Nishimoto N, Suzuki R, Itoh T. Mol Immunol 48 623-629 (2011)
  98. Comparative molecular and three-dimensional analysis of the peptide-MHC II binding region in both human and Aotus MHC-DRB molecules confirms their usefulness in antimalarial vaccine development. Patarroyo ME, Cifuentes G, Baquero J. Immunogenetics 58 598-606 (2006)
  99. Modeling of receptor mimics that inhibit superantigen pathogenesis. Möllhoff M, Zanden HB, Shiflett PR, Gupta G. J Mol Recognit 18 73-83 (2005)
  100. Overlap of direct and indirect alloreactive T-cell repertoires when MHC polymorphism is limited to the peptide binding groove. Battaglia M, Gorski J. Hum Immunol 63 91-100 (2002)
  101. Predicting Hemagglutinin MHC-II Ligand Analogues in Anti-TNFα Biologics: Implications for Immunogenicity of Pharmaceutical Proteins. Andrick BJ, Schwab AI, Cauley B, O'Donnell LA, Meng WS. PLoS One 10 e0135451 (2015)
  102. Protein design by fusion: implications for protein structure prediction and evolution. Skorupka K, Han SK, Nam HJ, Kim S, Faham S. Acta Crystallogr D Biol Crystallogr 69 2451-2460 (2013)
  103. A method to trap transient and weak interacting protein complexes for structural studies. Chichili VPR, Kumar V, Sivaraman J. Intrinsically Disord Proteins 1 e25464 (2013)
  104. Antigen identification for HLA class I- and HLA class II-restricted T cell receptors using cytokine-capturing antigen-presenting cells. Lee MN, Meyerson M. Sci Immunol 6 (2021)
  105. Comprehensive analysis and characterization of the TCR alpha chain sequences in the common marmoset. Fujii Y, Matsutani T, Kitaura K, Suzuki S, Itoh T, Takasaki T, Suzuki R, Kurane I. Immunogenetics 62 383-395 (2010)
  106. Increased positive selection pressure within the complementarity determining regions of the T-cell receptor β gene in New World monkeys. Matsutani T, Fujii Y, Kitaura K, Suzuki S, Tsuruta Y, Takasaki T, Ogasawara K, Nishimoto N, Kurane I, Suzuki R. Am J Primatol 73 1082-1092 (2011)
  107. MHC Bias by T Cell Receptors: Genetic Evidence for MHC and TCR Coevolution. Baker BM, Evavold BD. Trends Immunol 38 2-4 (2017)
  108. On recognizing 'shades-of-gray' (self-nonself discrimination) or 'colour' (Integrity model) by the immune system. Dembic Z. Scand J Immunol 78 325-338 (2013)
  109. Activation of a T cell hybridoma by an alloligand results in differential effects on IL-2 secretion and activation-induced cell death. Qadri A, Ward ES. Eur J Immunol 31 3825-3832 (2001)
  110. Affinity-matured HLA class II dimers for robust staining of antigen-specific CD4+ T cells. Sugata K, Matsunaga Y, Yamashita Y, Nakatsugawa M, Guo T, Halabelian L, Ohashi Y, Saso K, Rahman MA, Anczurowski M, Wang CH, Murata K, Saijo H, Kagoya Y, Ly D, Burt BD, Butler MO, Mak TW, Hirano N. Nat Biotechnol 39 958-967 (2021)
  111. Analysis of T cell receptor alpha-chain variable region (Valpha) usage and CDR3alpha of T cells infiltrated into lesions of psoriasis patients. Hwang HY, Kim TG, Kim TY. Mol Immunol 43 420-425 (2006)
  112. Elongating modified conserved peptides eliminates their immunogenicity and protective efficacy against P. falciparum malaria. Espejo F, Bermúdez A, Vanegas M, Rivera Z, Torres E, Salazar LM, Patarroyo ME. J Struct Biol 150 245-258 (2005)
  113. A Novel Cell-based Luciferase Reporter Platform for the Development and Characterization of T-Cell Redirecting Therapies and Vaccine Development. Grailer J, Cheng ZJ, Hartnett J, Slater M, Fan F, Cong M. J Immunother 46 96-106 (2023)
  114. A general chemical crosslinking strategy for structural analyses of weakly interacting proteins applied to preTCR-pMHC complexes. Mizsei R, Li X, Chen WN, Szabo M, Wang JH, Wagner G, Reinherz EL, Mallis RJ. J Biol Chem 296 100255 (2021)
  115. Contributions of the N-terminal flanking residues of an antigenic peptide from the Japanese cedar pollen allergen Cry j 1 to the T-cell activation by HLA-DP5. Kusano S, Ueda S, Oryoji D, Toyoumi A, Hashimoto-Tane A, Kishi H, Hamana H, Muraguchi A, Jin H, Arase H, Miyadera H, Kishikawa R, Yoshikai Y, Yamada H, Yamamoto K, Nishimura Y, Saito T, Sasazuki T, Yokoyama S. Int Immunol 35 447-458 (2023)
  116. Low CCR5 expression protects HIV-specific CD4+ T cells of elite controllers from viral entry. Claireaux M, Robinot R, Kervevan J, Patgaonkar M, Staropoli I, Brelot A, Nouël A, Gellenoncourt S, Tang X, Héry M, Volant S, Perthame E, Avettand-Fenoël V, Buchrieser J, Cokelaer T, Bouchier C, Ma L, Boufassa F, Hendou S, Libri V, Hasan M, Zucman D, de Truchis P, Schwartz O, Lambotte O, Chakrabarti LA. Nat Commun 13 521 (2022)
  117. Molecular basis of antigen recognition by insulin specific T cell receptor. Sugiyama S, Kohyama M, Oda M, Azuma T, Wither JE, Hozumi N. Immunol Lett 91 133-139 (2004)